RhoB controls endothelial cell morphogenesis in part via negative regulation of RhoA

Vascular Cell

Volumn 4, Issue , 2012, Pages

  Howe, Grant A ^a,b   Addison, Christina L ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

angiogenesis; capillary morphogenesis; endothelial; RhoA; RhoB; RhoC

Indexed keywords

EXOENZYME C3; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MORPHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84876393236     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-4-1     Document Type: Article

References (39)

1. Angiogenesis and vasculogenesis in rheumatoid arthritis. Szekanecz Z, Besenyei T, Szentpetery A, Koch AE, Curr Opin Rheumatol 2010 22 299 306 10.1097/BOR.0b013e328337c95a 20305562
2. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Tolentino MJ, Curr Mol Med 2009 9 973 981 10.2174/156652409789712783 19925410
3. Tumor angiogenesis. Kerbel RS, N Engl J Med 2008 358 2039 2049 10.1056/NEJMra0706596 18463380 (Pubitemid 351656458)
4. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Ranpura V, Hapani S, Chuang J, Wu S, Acta Oncol 2010 49 287 297 10.3109/02841860903524396 20156114
5. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. Ranpura V, Hapani S, Wu S, Jama 2011 305 487 494 10.1001/jama.2011.51 21285426
6. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Hapani S, Sher A, Chu D, Wu S, Oncology 2010 79 27 38 10.1159/000314980 21051914
7. GEFs and GAPs: critical elements in the control of small G proteins. Bos JL, Rehmann H, Wittinghofer A, Cell 2007 129 865 877 10.1016/j.cell.2007.05.018 17540168 (Pubitemid 46802708)
8. Post-translational modifications of p21rho proteins. Adamson P, Marshall CJ, Hall A, Tilbrook PA, J Biol Chem 1992 267 20033 20038 1400319
9. RHOB links pdgf signaling to cell migration by coordinating activation and localization of CDC42 and Rac. Huang M, Satchell L, Duhadaway JB, Prendergast GC, Laury-Kleintop LD, J Cell Biochem 2011 112 1572 84 10.1002/jcb.23069 21344485
10. Regulation of epidermal growth factor receptor traffic by the small GTPase rhoB. Gampel A, Parker PJ, Mellor H, Curr Biol 1999 9 955 958 10.1016/S0960-9822(99)80422-9 10508588 (Pubitemid 29442479)
11. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Wheeler AP, Ridley AJ, Exp Cell Res 2004 301 43 49 10.1016/j.yexcr.2004.08.012 15501444 (Pubitemid 39388895)
12. RhoA phosphorylation induces Rac1 release from guanine dissociation inhibitor alpha and stimulation of vascular smooth muscle cell migration. Rolli-Derkinderen M, Toumaniantz G, Pacaud P, Loirand G, Mol Cell Biol 2010 30 4786 4796 10.1128/MCB.00381-10 20696841
13. Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG, J Cell Biol 1999 147 1009 1022 10.1083/jcb.147.5.1009 10579721
14. RhoA-GDP regulates RhoB protein stability. Potential involvement of RhoGDIalpha. Ho TT, Merajver SD, Lapiere CM, Nusgens BV, Deroanne CF, J Biol Chem 2008 283 21588 21598 10.1074/jbc.M710033200 18524772
15. KDR stimulates endothelial cell migration through heterotrimeric G protein Gq/11-mediated activation of a small GTPase RhoA. Zeng H, Zhao D, Mukhopadhyay D, J Biol Chem 2002 277 46791 46798 10.1074/jbc.M206133200 12244099 (Pubitemid 35417683)
16. RhoC is essential for angiogenesis induced by hepatocellular carcinoma cells via regulation of endothelial cell organization. Wang W, Wu F, Fang F, Tao Y, Yang L, Cancer Sci 2008 99 2012 2018 19016761
17. What tangled webs they weave: Rho-GTPase control of angiogenesis. Bryan BA, D'Amore PA, Cell Mol Life Sci 2007 64 2053 2065 10.1007/s00018-007-7008-z 17530172 (Pubitemid 350092415)
18. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Adini I, Rabinovitz I, Sun JF, Prendergast GC, Benjamin LE, Genes Dev 2003 17 2721 2732 10.1101/gad.1134603 14597666 (Pubitemid 37363076)
19. MAP1A light chain-2 interacts with GTP-RhoB to control epidermal growth factor (EGF)-dependent EGF receptor signaling. Lajoie-Mazenc I, Tovar D, Penary M, Lortal B, Allart S, Favard C, Brihoum M, Pradines A, Favre G, J Biol Chem 2008 283 4155 4164 18056259
20. RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Huang M, Duhadaway JB, Prendergast GC, Laury-Kleintop LD, Arterioscler Thromb Vasc Biol 2007 27 2597 2605 10.1161/ATVBAHA.107.154211 17951322 (Pubitemid 350158911)
21. Transcriptional regulation of the small GTPase RhoB gene by TGF{beta}-induced signaling pathways. Vasilaki E, Papadimitriou E, Tajadura V, Ridley AJ, Stournaras C, Kardassis D, Faseb J 2010 24 891 905 10.1096/fj.09-134742 19890017
22. A novel mechanism of TGFbeta-induced actin reorganization mediated by Smad proteins and Rho GTPases. Vardouli L, Vasilaki E, Papadimitriou E, Kardassis D, Stournaras C, Febs J 2008 275 4074 4087 10.1111/j.1742-4658.2008. 06549.x 18631173
23. EGF modulation of the ras-related rhoB gene expression in human breast-cancer cell lines. de Cremoux P, Gauville C, Closson V, Linares G, Calvo F, Tavitian A, Olofsson B, Int J Cancer 1994 59 408 415 10.1002/ijc.2910590320 7927950 (Pubitemid 24331835)
24. MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells. Sabatel C, Malvaux L, Bovy N, Deroanne C, Lambert V, Gonzalez ML, Colige A, Rakic JM, Noel A, Martial JA, Struman I, PLoS One 2011 6 16979 10.1371/journal.pone.0016979 21347332
25. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, Johnson GL, J Biol Chem 2010 285 11760 11764 10.1074/jbc.C109. 097220 20181950
26. Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis. Kroll J, Epting D, Kern K, Dietz CT, Feng Y, Hammes HP, Wieland T, Augustin HG, Am J Physiol Heart Circ Physiol 2009 296 893 899 10.1152/ajpheart.01038.2008 19181962
27. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R, Mak TW, Genes Dev 2005 19 1974 1979 10.1101/gad.1310805 16107613 (Pubitemid 41247955)
28. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD, Mol Cancer Ther 2002 1 575 583 12479217
29. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, Mercurio AM, Oncogene 2006 25 6959 6967 10.1038/sj.onc.1209682 16715134 (Pubitemid 44684836)
30. RhoGDIalpha-dependent balance between RhoA and RhoC is a key regulator of cancer cell tumorigenesis. Ho TTG, Stultiens A, Dubail J, Lapiere CM, Nusgens BV, Colige AC, Deroanne CF, Molecular Biology of the Cell 2011 22 3263 3275 10.1091/mbc.E11-01-0020 21757538
31. Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1. Boulter E, Garcia-Mata R, Guilluy C, Dubash A, Rossi G, Brennwald PJ, Burridge K, Nat Cell Biol 2010 12 477 483 10.1038/ncb2049 20400958
32. Coordination of Rho GTPase activities during cell protrusion. Machacek M, Hodgson L, Welch C, Elliott H, Pertz O, Nalbant P, Abell A, Johnson GL, Hahn KM, Danuser G, Nature 2009 461 99 103 10.1038/nature08242 19693013
33. GEF-H1 modulates localized RhoA activation during cytokinesis under the control of mitotic kinases. Birkenfeld J, Nalbant P, Bohl BP, Pertz O, Hahn KM, Bokoch GM, Dev Cell 2007 12 699 712 10.1016/j.devcel.2007.03.014 17488622 (Pubitemid 46671149)
34. Spatiotemporal dynamics of RhoA activity in migrating cells. Pertz O, Hodgson L, Klemke RL, Hahn KM, Nature 2006 440 1069 1072 10.1038/nature04665 16547516
35. Regulation of Ras-related RhoB protein expression during the cell cycle. Zalcman G, Closson V, Linares-Cruz G, Lerebours F, Honore N, Tavitian A, Olofsson B, Oncogene 1995 10 1935 1945 7539118
36. XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC. Arthur WT, Ellerbroek SM, Der CJ, Burridge K, Wennerberg K, J Biol Chem 2002 277 42964 42972 10.1074/jbc.M207401200 12221096 (Pubitemid 35285675)
37. Characterization of G alpha 13-dependent plasma membrane recruitment of p115RhoGEF. Bhattacharyya R, Wedegaertner PB, Biochem J 2003 371 709 720 10.1042/BJ20021897 12534370 (Pubitemid 36578870)
38. Rapid recruitment of p120RasGAP and its associated protein, p190RhoGAP, to the cytoskeleton during integrin mediated cell-substrate interaction. Sharma SV, Oncogene 1998 17 271 281 10.1038/sj.onc.1201921 9690509 (Pubitemid 28383004)
39. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC, Oncogene 2003 22 1124 1134 10.1038/sj.onc.1206181 12606940 (Pubitemid 36363378)